A study published in the New England Journal of Medicine looks at nirsevimab for the prevention of RSV hospitalisations in infants. … read more
A press release from GSK states that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Arexvy, the first … read more
A Sanofi press release suggests that their antibody treatment, nirsevimab, delivers 83% reduction in RSV infant hospitalizations in a real-world clinical … read more
An investigation by the BMJ urges further analysis on maternal RSV vaccines and preterm births. Prof Christopher Chiu, Professor … read more
Respiratory Syncytial Virus (RSV) is a common seasonal virus that infects most babies in their first few years of life. … read more
A press release from Pfizer gives top line data from the phase 3 maternal immunisation trial of its bivalent Respiratory … read more
A press release from GSK announces the phase III trial results for their respiratory syncytial virus (RSV) vaccine candidate for … read more